ATS 2024 Final Program

Click on the session title to view the speakers

297

TUESDAY • MAY 21

BEHAVIORAL • CLINICAL MINI SYMPOSIUM

CLINICAL MINI SYMPOSIUM

C94 ASTHMA QUALITY IMPROVEMENT, HEALTH SERVICES RESEARCH, AND DISPARITIES 2:15 p.m. - 4:15 p.m. San Diego Convention Center Room 28A-B (Upper Level) Oral Presentations: 2:15 Utilization of Single Maintenance and Reliever Therapy (SMART) for Moderate and Severe Asthma 2:27 Development of a Patient-Centered Asthma Action Plan for Single Maintenance and Reliever Therapy (SMART) 2:39 Association Between Industry Payments and Prescription of Inhaled Medications: An Observational Analysis of Open Payments and Medicare Part D Data 2:51 Differences in Reported Use of Inhaled Corticosteroids in Hispanic Adults With Asthma: Findings From the 2014-2020 U.S. Asthma Call Back Survey 3:03 Unveiling the Real-World Causal Interaction of Essential Risk Factors in Severe Asthma Exacerbation: A Bayesian Network Analysis 3:15 Both Moderate-Intensity and Vigorous-Intensity Aerobic Exercise Training Are Associated With Clinical Improvements in Asthma 3:27 Physical Activity Variability and Lung Function in Urban Children With Asthma 3:39 Individual and System-level Determinants of Caregiver’s Quality of Life Among Inner-city Preschool Children With Asthma 3:51 Identification of Barriers to Seeing a Healthcare Provider Among Rural Adolescents With Poorly Controlled Asthma 4:03 Out-of-Pocket Prescription Drug Savings for

C95 NEW CLINICAL TRIAL RESULTS IN CHRONIC LUNG DISEASE 2:15 p.m. - 4:15 p.m. San Diego Convention Center Ballroom 20A (Upper Level) Oral Presentations: 2:15 Zinpentraxin Alfa in Patients With Idiopathic Pulmonary Fibrosis: Results and Learnings From the Phase III STARSCAPE Trial 2:27 The Bisoprolol in COPD Study (BICS): A UK Randomized Controlled Trial of Bisoprolol in People With COPD at Risk of Exacerbation 2:39 Pamrevlumab for Idiopathic Pulmonary Fibrosis: Results of the Phase 3 Zephyrus-1 Study 2:51 Ensifentrine Added on to LAMA Therapy Improved Lung Function and Reduced Exacerbations in Symptomatic Subjects With Moderate-to-Severe COPD 3:03 Effect of BMS-986278, An Oral LPA1 Antagonist, on Time to Disease Progression in Patients With Pulmonary Fibrosis: A Post Hoc Analysis of Data From a Phase 2 Randomized Trial 3:15 Beta-blocker Use and Clinical Outcomes in Patients With COPD and Acute Myocardial Infarction: Results From the BLOCK-COPD Observational Study 3:27 Inhaled Nitric Oxide in Fibrotic Lung Disease: A Randomized, Double-blind, Placebo-controlled Trial 3:39 Impact of an Integrated Care Program (AIREPOC) on COPD Outcomes According to Wood or Tobacco Exposure 3:51 Update on the Safety and Tolerability of Bexotegrast, A Dual-selective Inhibitor of Integrins avß6 and avß1, in Development for Idiopathic Pulmonary Fibrosis and Primary Sclerosing Cholangitis 4:03 In the Phase 3 Boreas Trial, Baseline Blood Eosinophils and Baseline Fractional Exhaled Nitric Oxide Levels Predict the Response to Dupilumab in

Medicare Beneficiaries With Obstructive Lung Disease Under the Inflation Reduction Act

Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

ATS 2024 Conference Program • San Diego, CA